Azilect and Rasagiline: Generic Name Clarification
Azilect is the brand name for rasagiline, not a separate medication—they are the same drug. 1
Drug Identity
Azilect® tablets contain rasagiline mesylate as the active pharmaceutical ingredient. Each tablet contains rasagiline mesylate equivalent to either 0.5 mg or 1 mg of rasagiline base. 1
The chemical designation is: 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-, methanesulfonate, with the empirical formula (C12H13N)CH4SO3 and molecular weight of 267.34. 1
Clinical Context
Rasagiline is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for treating idiopathic Parkinson's disease as either:
- Initial monotherapy (1 mg once daily) 1
- Adjunct therapy to levodopa (0.5 mg once daily, may increase to 1 mg daily as needed) 1
The drug functions by irreversibly inhibiting MAO-B, which increases extracellular dopamine levels in the striatum, thereby mediating beneficial effects in dopaminergic motor dysfunction. 1 Unlike the related compound selegiline, rasagiline possesses no amphetamine-like properties. 2
Generic Availability
Generic formulations of rasagiline are available in the United States as of March 2026. 3 These generic versions contain the same active ingredient (rasagiline) at the same doses (0.5 mg and 1 mg) as the brand-name Azilect.
Key point: When prescribing or discussing this medication, "Azilect" and "rasagiline" refer to the identical drug—Azilect is simply the proprietary brand name manufactured by Teva Pharmaceutical Industries, while rasagiline is the generic (chemical) name used for both branded and generic formulations.